Regenxbio (RGNX) Capital Expenditures (2015 - 2025)

Regenxbio's Capital Expenditures history runs 11 years deep, the most recent figure standing at $2.1 million for Q4 2025.

• On a quarterly basis, Capital Expenditures rose 746.39% year-over-year to $2.1 million in Q4 2025; TTM through Dec 2025 was $2.4 million, a 399.13% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 399.13% from the prior year.
• Capital Expenditures declined to $2.1 million in Q4 2025 per RGNX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $67.1 million in Q3 2021 and bottomed at -$67.3 million in Q4 2021.
• The 5-year median for Capital Expenditures is $790500.0 (2024), against an average of $112900.0.
• Across the five-year window, Capital Expenditures soared 827.81% in 2021 and tumbled 735.03% in 2022, its largest moves.
• Year by year, Capital Expenditures stood at -$67.3 million in 2021, then soared by 97.1% to -$2.0 million in 2022, then tumbled by 433.74% to -$10.4 million in 2023, then surged by 96.82% to -$332000.0 in 2024, then soared by 746.39% to $2.1 million in 2025.
• Per Business Quant, the three latest RGNX Capital Expenditures figures stand at $2.1 million (Q4 2025), $2.4 million (Q3 2025), and -$3.1 million (Q2 2025).